0001213900-25-029501.txt : 20250408 0001213900-25-029501.hdr.sgml : 20250408 20250407174047 ACCESSION NUMBER: 0001213900-25-029501 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250404 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250408 DATE AS OF CHANGE: 20250407 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39685 FILM NUMBER: 25819177 BUSINESS ADDRESS: STREET 1: 1445-885 WEST GEORGIA ST. CITY: VANCOUVER STATE: A1 ZIP: V6C 3E8 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: 1445-885 WEST GEORGIA ST. CITY: VANCOUVER STATE: A1 ZIP: V6C 3E8 8-K 1 ea0237298-8k_inmed.htm CURRENT REPORT
false 0001728328 A1 0001728328 2025-04-04 2025-04-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 4, 2025

 

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

 

British Columbia   001-39685   98-1428279
(State or Other Jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

InMed Pharmaceuticals Inc.    
Suite 1445 - 885 W. Georgia Street,    
Vancouver, B.C.    
Canada   V6C 3E8
(Address of Principal Executive Offices)   (Zip Code)

 

Company’s telephone number, including area code: (604) 669-7207

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Shares, no par value   INM   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 Other Events

 

On April 4, 2025, InMed Pharmaceuticals Inc. (the “Company”) announced the meeting, record date and certain other information relating to a special meeting of the Company’s shareholders to be held on June 13, 2025, pursuant to a filing submitted to the System for Electronic Document Analysis and Retrieval (“SEDAR”) in Canada.

 

The information set forth in this Item 8.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 8.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

The following exhibits shall be deemed to be furnished, and not filed:

 

Exhibit No   Description
99.1   SEDAR filing submitted April 4, 2025
104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INMED PHARMACEUTICALS INC.
     
Date: April 7, 2025 By: /s/ Eric A. Adams
    Eric A. Adams
    President and CEO

 

 

2

 

 EX-99.1 2 ea023729801ex99-1_inmed.htm SEDAR FILING SUBMITTED APRIL 4, 2025

Exhibit 99.1

 

April 4, 2025

 

Filed via SEDAR+

 

To All Applicable Exchanges and Securities Administrators

 

Subject:InMed Pharmaceuticals Inc. (the “Issuer”)
 Notice of Meeting and Record Date

 

Dear Sir/Madam:

 

We are pleased to confirm the following information with respect to the Issuer’s upcoming meeting of securityholders:

 

Meeting Type: Special Meeting
Meeting Date: June 13, 2025
Record Date for Notice of Meeting: April 29, 2025
Record Date for Voting (if applicable): April 29, 2025
Beneficial Ownership Determination Date: April 29, 2025
Class of Securities Entitled to Vote: Common Shares
ISIN: CA4576377002
Issuer sending proxy materials directly to NOBOs: No
Issuer paying for delivery to OBOs: No
Notice and Access for Beneficial Holders: Yes
Notice and Access for Registered Holders: Yes

 

In accordance with applicable securities regulations we are filing this information with you in our capacity as agent of the Issuer.

 

Yours truly,

 

Odyssey Trust Company

as agent for InMed Pharmaceuticals Inc.

 

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end EX-101.SCH 4 inm-20250404.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 inm-20250404_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 inm-20250404_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover
Apr. 04, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 04, 2025
Entity File Number 001-39685
Entity Registrant Name INMED PHARMACEUTICALS INC.
Entity Central Index Key 0001728328
Entity Tax Identification Number 98-1428279
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One Suite 1445 - 885 W. Georgia Street
Entity Address, City or Town Vancouver
Entity Address, Country CA
Entity Address, Postal Zip Code V6C 3E8
City Area Code 604
Local Phone Number 669-7207
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol INM
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inmedpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea0237298-8k_inmed.htm inm-20250404.xsd inm-20250404_lab.xml inm-20250404_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0237298-8k_inmed.htm": { "nsprefix": "INM", "nsuri": "http://inmedpharma.com/20250404", "dts": { "inline": { "local": [ "ea0237298-8k_inmed.htm" ] }, "schema": { "local": [ "inm-20250404.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "inm-20250404_lab.xml" ] }, "presentationLink": { "local": [ "inm-20250404_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://inmedpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2025-04-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0237298-8k_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-04-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0237298-8k_inmed.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001213900-25-029501-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-25-029501-xbrl.zip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ea0237298-8k_inmed_htm.xml IDEA: XBRL DOCUMENT 0001728328 2025-04-04 2025-04-04 iso4217:USD shares iso4217:USD shares false 0001728328 A1 8-K 2025-04-04 INMED PHARMACEUTICALS INC. 001-39685 98-1428279 Suite 1445 - 885 W. Georgia Street Vancouver CA V6C 3E8 604 669-7207 false false false false Common Shares, no par value INM NASDAQ true false